• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

自身免疫过程中FcRn在抗原呈递细胞中的作用以及艾加莫德作为FcRn阻断剂的临床评估

Roles of FcRn in Antigen-Presenting Cells during Autoimmunity and a Clinical Evaluation of Efgartigimod as an FcRn Blocker.

作者信息

Zhou Yihan, Jiang Shisong

机构信息

Department of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK.

出版信息

Pathogens. 2023 Jun 8;12(6):817. doi: 10.3390/pathogens12060817.

DOI:10.3390/pathogens12060817
PMID:37375507
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10303165/
Abstract

The immune system is a complex network of multiple cells, tissues, and organs that protects the body against foreign pathogenic invaders. However, the immune system may mistakenly attack healthy cells and tissues due to the cross-reactivity of anti-pathogen immunity, leading to autoimmunity by autoreactive T cells and/or autoantibody-secreting B cells. Autoantibodies can accumulate, resulting in tissue or organ damage. The neonatal crystallizable fragment receptor (FcRn) is an important factor in immune regulation through controlling the trafficking and recycling of immunoglobulin G (IgG) molecules, the most abundant antibody in humoral immunity. In addition to its role in IgG trafficking and recycling, FcRn is also involved in antigen presentation, which is a crucial step in the activation of the adaptive immune response via directing the internalization and trafficking of antigen-bound IgG immune complexes into compartments of degradation and presentation in antigen-presenting cells. Efgartigimod, an FcRn inhibitor, has shown promise in reducing the levels of autoantibodies and alleviating the autoimmune severity of myasthenia gravis, primary immune thrombocytopenia, and pemphigus vulgaris/foliaceus. This article aims to provide an overview of the importance of FcRn in antigen-presenting cells and its potential as a therapeutic target in autoimmune diseases, using efgartigimod as an example.

摘要

免疫系统是一个由多种细胞、组织和器官组成的复杂网络,它保护身体免受外来致病入侵者的侵害。然而,由于抗病原体免疫的交叉反应性,免疫系统可能会错误地攻击健康细胞和组织,导致自身反应性T细胞和/或分泌自身抗体的B细胞引发自身免疫。自身抗体可能会积累,导致组织或器官损伤。新生儿可结晶片段受体(FcRn)是免疫调节中的一个重要因素,它通过控制体液免疫中最丰富的抗体——免疫球蛋白G(IgG)分子的运输和循环来发挥作用。除了在IgG运输和循环中的作用外,FcRn还参与抗原呈递,这是通过将与抗原结合的IgG免疫复合物内化并运输到抗原呈递细胞中的降解和呈递区室,从而激活适应性免疫反应的关键步骤。FcRn抑制剂艾加莫德已显示出有望降低自身抗体水平,并减轻重症肌无力、原发性免疫性血小板减少症和寻常型/落叶型天疱疮的自身免疫严重程度。本文旨在以艾加莫德为例,概述FcRn在抗原呈递细胞中的重要性及其作为自身免疫性疾病治疗靶点的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/847f/10303165/fb932b6db7b0/pathogens-12-00817-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/847f/10303165/fb932b6db7b0/pathogens-12-00817-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/847f/10303165/fb932b6db7b0/pathogens-12-00817-g001.jpg

相似文献

1
Roles of FcRn in Antigen-Presenting Cells during Autoimmunity and a Clinical Evaluation of Efgartigimod as an FcRn Blocker.自身免疫过程中FcRn在抗原呈递细胞中的作用以及艾加莫德作为FcRn阻断剂的临床评估
Pathogens. 2023 Jun 8;12(6):817. doi: 10.3390/pathogens12060817.
2
FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus.FcRn 拮抗剂导致桥粒芯糖蛋白特异性 B 细胞减少:以 Efgartigimod 在寻常型天疱疮和落叶型天疱疮的 2 期研究为基础的二次分析。
Front Immunol. 2022 May 18;13:863095. doi: 10.3389/fimmu.2022.863095. eCollection 2022.
3
Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis.艾加莫德治疗重症肌无力的临床疗效与安全性
Immunotherapy. 2023 Jun;15(8):553-563. doi: 10.2217/imt-2022-0298. Epub 2023 Apr 4.
4
Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis.FcRn 拮抗作用对 IgG 介导的自身免疫性疾病天疱疮和重症肌无力中保护性抗体和疫苗的影响。
Autoimmunity. 2022 Dec;55(8):620-631. doi: 10.1080/08916934.2022.2104261. Epub 2022 Aug 29.
5
Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus?通过依库珠单抗阻断 FcRn 稳定抗桥粒芯糖蛋白 3 抗体诱导的角质形成细胞单层完整性:天疱疮的新治疗策略?
Cells. 2022 Mar 10;11(6):942. doi: 10.3390/cells11060942.
6
Efgartigimod as a novel FcRn inhibitor for autoimmune disease.艾加莫德作为一种用于自身免疫性疾病的新型FcRn抑制剂。
Neurol Sci. 2024 Sep;45(9):4229-4241. doi: 10.1007/s10072-024-07460-5. Epub 2024 Apr 22.
7
[Neonatal Fc receptor (FcRn)-A Novel Therapeutic Approach for Autoimmune Disease].[新生儿Fc受体(FcRn)——自身免疫性疾病的一种新型治疗方法]
Brain Nerve. 2024 Feb;76(2):183-191. doi: 10.11477/mf.1416202582.
8
Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention.人类免疫中的新生儿 Fc 受体:功能与治疗干预中的作用。
J Allergy Clin Immunol. 2020 Sep;146(3):467-478. doi: 10.1016/j.jaci.2020.07.015.
9
Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome.依氟鸟氨酸治疗重症肌无力之外:FcRn 靶向治疗在僵人综合征中的作用。
J Neurol. 2024 Jan;271(1):254-262. doi: 10.1007/s00415-023-11970-1. Epub 2023 Sep 8.
10
FcRn inhibitors: a novel option for the treatment of myasthenia gravis.FcRn抑制剂:治疗重症肌无力的新选择。
Neural Regen Res. 2023 Aug;18(8):1637-1644. doi: 10.4103/1673-5374.363824.

引用本文的文献

1
The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis.艾加莫德治疗难治性重症肌无力的疗效和安全性:一项系统评价与荟萃分析
Eur J Med Res. 2025 Aug 20;30(1):775. doi: 10.1186/s40001-025-03057-6.
2
Efgartigimod therapy for immune checkpoint inhibitor-associated myasthenia gravis with myositis: a case report.艾加莫德治疗免疫检查点抑制剂相关重症肌无力伴肌炎:一例报告
BMC Neurol. 2025 Jul 4;25(1):276. doi: 10.1186/s12883-025-04288-0.
3
Short-term treatment of CIDP with efgartigimod: a case series in China.

本文引用的文献

1
The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention.自身免疫和自身免疫性疾病的患病率不断上升:急需采取行动以提高认识、诊断、治疗和预防水平。
Curr Opin Immunol. 2023 Feb;80:102266. doi: 10.1016/j.coi.2022.102266. Epub 2022 Nov 26.
2
Targeted inhibition of FcRn reduces NET formation to ameliorate experimental ulcerative colitis by accelerating ANCA clearance.靶向抑制 FcRn 减少 NET 形成,通过加速 ANCA 清除来改善实验性溃疡性结肠炎。
Int Immunopharmacol. 2022 Dec;113(Pt B):109474. doi: 10.1016/j.intimp.2022.109474. Epub 2022 Nov 20.
3
用艾加莫德治疗慢性炎性脱髓鞘性多发性神经病的短期治疗:中国的病例系列
Front Immunol. 2025 May 1;16:1533167. doi: 10.3389/fimmu.2025.1533167. eCollection 2025.
4
A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database.在FDA不良事件报告系统数据库中开展的关于阿伐吉莫德的真实世界药物警戒研究。
Front Pharmacol. 2025 Apr 16;16:1510992. doi: 10.3389/fphar.2025.1510992. eCollection 2025.
5
Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects.人骨髓瘤中的单克隆抗CD38疗法:回顾与展望。
Front Immunol. 2025 Feb 12;16:1519300. doi: 10.3389/fimmu.2025.1519300. eCollection 2025.
6
Case report: Rapid symptom relief in autoimmune encephalitis with efgartigimod: a three-patient case series.病例报告:依氟鸟氨酸治疗自身免疫性脑炎的快速症状缓解:三例病例系列。
Front Immunol. 2024 Oct 3;15:1444288. doi: 10.3389/fimmu.2024.1444288. eCollection 2024.
7
Resolution of anti-LGI1-associated autoimmune encephalitis in a patient after treatment with efgartigimod.一名患者在接受艾加莫德治疗后,抗LGI1相关自身免疫性脑炎得到缓解。
J Neurol. 2024 Sep;271(9):5911-5915. doi: 10.1007/s00415-024-12556-1. Epub 2024 Jul 9.
8
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study.尼泊利单抗,一种抗 FcRn 单克隆抗体,在对 TNF 治疗反应不足或不耐受的中重度活动性类风湿关节炎患者中的疗效:来自 2a 期 IRIS-RA 研究的结果。
RMD Open. 2024 Jun 28;10(2):e004278. doi: 10.1136/rmdopen-2024-004278.
9
Rescue treatment with add-on efgartigimod in a patient with impending myasthenic crisis: a case report.在一名即将发生重症肌无力危象的患者中加用艾加莫德进行抢救治疗:一例病例报告
Ther Adv Neurol Disord. 2024 May 28;17:17562864241254895. doi: 10.1177/17562864241254895. eCollection 2024.
Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies.
慢性自身免疫性脱髓鞘性神经病的治疗性单克隆抗体治疗。
Neurotherapeutics. 2022 Apr;19(3):874-884. doi: 10.1007/s13311-022-01222-x. Epub 2022 Mar 28.
4
Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial.以新生儿 Fc 受体抑制剂 efgartigimod 治疗寻常型天疱疮和落叶型天疱疮:一项 II 期多中心、开放性可行性试验。
Br J Dermatol. 2022 Mar;186(3):429-439. doi: 10.1111/bjd.20782. Epub 2021 Nov 28.
5
Differentiating Pemphigus Foliaceus From Pemphigus Vulgaris in Clinical Practice.临床实践中鉴别落叶型天疱疮与寻常型天疱疮。
Cureus. 2021 Sep 11;13(9):e17889. doi: 10.7759/cureus.17889. eCollection 2021 Sep.
6
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.依氟鸟氨酸苷单抗在全身性重症肌无力患者中的安全性、疗效和耐受性(ADAPT):一项多中心、随机、安慰剂对照、3 期临床试验。
Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9.
7
Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations.重症肌无力:流行病学、病理生理学及临床表现
J Clin Med. 2021 May 21;10(11):2235. doi: 10.3390/jcm10112235.
8
Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management.原发性免疫性血小板减少症:病理生理学与疾病管理的新见解
J Clin Med. 2021 Feb 16;10(4):789. doi: 10.3390/jcm10040789.
9
An updated advance of autoantibodies in autoimmune diseases.自身免疫性疾病中自身抗体的最新进展。
Autoimmun Rev. 2021 Feb;20(2):102743. doi: 10.1016/j.autrev.2020.102743. Epub 2020 Dec 14.
10
Lysosome as a Central Hub for Rewiring PH Homeostasis in Tumors.溶酶体作为肿瘤中重新调节pH稳态的核心枢纽。
Cancers (Basel). 2020 Aug 27;12(9):2437. doi: 10.3390/cancers12092437.